First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Clinical trial NCT06130722 · COMPLETED

Trial details

NCT number: NCT06130722
Sponsor: Suzhou Forlong Biotechnology Co., Ltd
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Locally Advanced/Metastatic Solid Tumors

Start date: 2023-12-30
Primary completion: 2025-02-15
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.